French MRI (magnetic resonance imaging) market will take time to recover:
This article was originally published in Clinica
Executive Summary
The price of MRI systems in France is 12-15% below the world average, according to the French industry association, SNITEM. The reason for this is the traditional low investment in this area, which has increased competition and forced down prices. " Brazil and Mexico are more attractive markets than France," believes Andre Guinet, of Philips Medical Systems (France). The government's recent decision to authorise a 50% increase in the provision of MRI systems in France has been welcomed by industry, but many believe this is not enough. "It will be mid-2002 before the majority of these systems are operational given the long delay between the announcement of this decision and the effective installation," Mr Guinet said.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.